402 related articles for article (PubMed ID: 28271256)
1. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
4. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.
Sanghavi K; Brundage RC; Miller MB; Schladt DP; Israni AK; Guan W; Oetting WS; Mannon RB; Remmel RP; Matas AJ; Jacobson PA
Pharmacogenomics J; 2017 Jan; 17(1):61-68. PubMed ID: 26667830
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
6. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing.
Yoon JG; Song SH; Choi S; Oh J; Jang IJ; Kim YJ; Moon S; Kim BJ; Cho Y; Kim HK; Min S; Ha J; Shin HS; Yang CW; Yoon HE; Yang J; Lee MG; Park JB; Kim MS;
Transplantation; 2021 Oct; 105(10):2213-2225. PubMed ID: 33654003
[TBL] [Abstract][Full Text] [Related]
8. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
9. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation.
David-Neto E; Romano P; Kamada Triboni AH; Ramos F; Agena F; Almeida Rezende Ebner P; Altona M; Galante NZ; Brambate Carvalhinho Lemos F
Transplantation; 2017 Jun; 101(6):1365-1372. PubMed ID: 27482958
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.
Kagaya H; Niioka T; Saito M; Inoue T; Numakura K; Yamamoto R; Akamine Y; Habuchi T; Satoh S; Miura M
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29547545
[TBL] [Abstract][Full Text] [Related]
13. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
[TBL] [Abstract][Full Text] [Related]
15. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
Cusinato DA; Lacchini R; Romao EA; Moysés-Neto M; Coelho EB
Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
[TBL] [Abstract][Full Text] [Related]
16. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
17. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
18. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
[TBL] [Abstract][Full Text] [Related]
19. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients.
Zhang J; Zhang X; Liu L; Tong W
Transplant Proc; 2010 Nov; 42(9):3459-64. PubMed ID: 21094797
[TBL] [Abstract][Full Text] [Related]
20. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
